Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2 Study of Selinexor With Dexamethasone, Ifosfamide, Carboplatin, and Etoposide in Patients Who Have Secondary Central Nervous System Involvement With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

NCT06552559 is registered in ClinicalTrials.gov with Samsung Medical Center as lead sponsor.

NCT NCT06552559
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06552559 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2 Study of Selinexor With Dexamethasone, Ifosfamide, Carboplatin, and Etoposide in Patients Who Have Secondary Central Nervous System Involvement With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Lead sponsor
Samsung Medical Center
Phase
Phase 1/2
Overall status
Recruiting
Start date
May 1, 2024
Completion date
December 30, 2028
Enrollment
37 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell lymphoma recurrent, b-cell lymphoma refractory, cns metastases